Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Phillip Koeffler

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Expert Opinion on Therapeutic Targets|July 1, 2014
LAMC2 as a therapeutic target for cancersManoj Garg, Glenn Braunstein, Harold Phillip Koeffler
Oncotarget|September 10, 2021
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation statusHélène Marijon, Sigal Gery, Hua Chang, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Expert Opinion on Therapeutic Targets|July 1, 2014
LAMC2 as a therapeutic target for cancersManoj Garg, Glenn Braunstein, Harold Phillip Koeffler
Oncotarget|September 10, 2021
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation statusHélène Marijon, Sigal Gery, Hua Chang, et al.
Pageof 1